Go to content
UR Home

Comparison of the oncolytic activity of a replication‐competent and a replication‐deficient herpes simplex virus 1

URN to cite this document:
urn:nbn:de:bvb:355-epub-578826
DOI to cite this document:
10.5283/epub.57882
Lindner, Georg ; Walter, Annika ; Magnus, Clara L. ; Rosenhammer, Katharina ; Holoborodko, Bohdan ; Koch, Victoria ; Hirsch, Sarah ; Grossmann, Luis ; Li, Suqi ; Knipe, David M. ; DeLuca, Neal ; Schuler‐Thurner, Beatrice ; Gross, Stefanie ; Schwertner, Barbara ; Toelge, Martina ; Rohrhofer, Anette ; Stöckl, Sabine ; Bauer, Richard J. ; Knoll, Gertrud ; Ehrenschwender, Martin ; Haferkamp, Sebastian ; Schmidt, Barbara ; Schuster, Philipp
Date of publication of this fulltext: 12 Mar 2024 07:12

This publication is part of the DEAL contract with Wiley.


Abstract

In 2015, the oncolytic herpes simplex virus 1 (HSV-1) T-VEC (talimogene laherparepvec) was approved for intratumoral injection in non-resectable malignant melanoma. To determine whether viral replication is required for oncolytic activity, we compared replication-deficient HSV-1 d106S with replication-competent T-VEC. High infectious doses of HSV-1 d106S killed melanoma (n = 10), head-and-neck ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons